- Acute Coronary Syndromes
- Blood
- Cardiomyopathy
- Congenital Disorders
- Coronary Artery Disease
- Electrophysiology & Arrhythmia
- Heart Failure
- Imaging & Diagnostics
- Intervention
- Myocardial Infarction
- Pericardium Disorders
- Practice Management
- Prevention / Risk
- Pulmonary Arterial Hypertension
- Rehabilitation
- Standards & Guidelines
- Stroke
- Surgery
Perspective on the Use of True Vessel Characterization Imaging in Interventional Cardiology Clinical Practice
Interventional Cardiology 2012;7(1):17–20
Abstract
Intracoronary near infrared spectroscopy (NIRS), incorporated in the True Vessel Characterization (TVC) Imaging System™, is a novel method for the identification and quantification of lipid composition in coronary plaques. The main advantage of NIRS over other plaque characterisation methods is its ability to directly identify chemical composition – the primary use of spectroscopy for other applications. NIRS by itself does not display structures, but a combination device with co-registered intravascular ultrasound (IVUS) has been developed to give simultaneous and complementary structural and compositional information. Identification of lipid core plaque with NIRS hypothetically has the potential to optimise the length of vessel to stent and to lead to effective utilisation of embolic protection devices in the native coronaries, identifying the exact location of lipid-core lesions at high risk of distal embolisation. The NIRS-IVUS device also has promise in the identification of vulnerable plaque, which may lead to strategies to prevent future coronary events.Acknowledgement: The authors would like to thank Sean Madden from InfraReDx for his help in the preparation of the article.
Support: The publication of this article was funded by InfraReDx. The views and opinions expressed are those of the authors and not necessarily those of InfraReDx.
Keywords
Lipid core plaque, near infrared spectroscopy, vulnerable plaque
Lipid core plaque, near infrared spectroscopy, vulnerable plaque
Disclosure
The authors have no conflicts of interest to declare.
Received:
December 17, 2011 |
Accepted
January 30, 2012 |
Citation
Interventional Cardiology 2012;7(1):17–20
Correspondence:
Patrick W Serruys, Head of the Interventional Cardiology Department, Erasmus MC, Thoraxcenter, ‘s Gravendijkwal 230,3015 CE, Rotterdam, The Netherlands. E: p.w.j.c.serruys@erasmusmc.nl







